Skip to main content

Research empowerment on solute carriers

ReSOLUTE

Start Date
End Date
Total Funding
€ 23 850 000
Funding Programme
European Countries Involved

Transport proteins are the gate-keepers of our cells, effectively controlling the flow of nutrients and other molecules across the cell membrane. With over 400 members, solute carriers represent the largest class of transport proteins. Yet although they have been implicated in diseases ranging from Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) to schizophrenia, solute carriers have never been studied in detail.The ReSOLUTE project aims to change that, by intensifying research in, and advancing our knowledge of, the solute carrier family. Specifically, the project partners plan to deliver practical research tools, protocols, databases and platforms on solute carriers. The project’s open access ethos means the results will be of benefit to researchers in universities as well as small and large biotech companies worldwide. Ultimately, the project results will aid in the identification of solute carriers that could be used as either drug targets or as pathways for enabling the transport of medicines into specific tissues.

Project partners

Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh
The Chancellor
Masters And Scholars Of The University Of Oxford
The University Of Manchester
Axxam Spa
Universiteit Leiden
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev
Universitat Wien
Pfizer Limited
Novartis Pharma Ag
Boehringer Ingelheim Internationalgmbh
Vifor (International) Ag
Sanofi-Aventis Recherche & Developpement
Bayer Aktiengesellschaft
The University Of Liverpool

 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).